Implantica presents at Redeye Future of Healthcare Seminar
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, announces that on Thursday, March 30, at 14:45, Peter Forsell presents Implantica and it’s latest developments at Redeye’s Future of Healthcare Seminar.
The presentation will be live broadcasted in English and can be followed at: https://www.redeye.se/events/870753/redeye-future-of-healthcare-event where the replay and the presentation will be available afterwards.
For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, firstname.lastname@example.org
The information was sent for publication, through the agency of the contact person set out above, on March 29, 2023, at 8:30 a.m. CET.
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that has the potential to create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
VP Marketing & Advocacy